Tropicana Entertainment Inc. Assigned 'BB-' Corporate Credit Rating; Outlook Is Stable Feb 12

  • ID: 2055060
  • February 2012
  • Standard & Poors
1 of 3

Las Vegas-based gaming operator Tropicana Entertainment Inc. plans to raise a $175 million senior secured term loan due 2018, the proceeds of which will be used to refinance its existing debt and add cash to the balance sheet. We are assigning our 'BB-' corporate credit rating to the company and assigning our 'BB+' issue-level rating to the proposed senior secured term loan. The stable rating outlook reflects our expectation that credit measures will remain in line with the rating, despite competitive pressures facing two key existing properties and our belief that management will actively pursue expansion or acquisition opportunities. NEW YORK (Standard & Poor's) Feb. 10, 2012--Standard & Poor's Ratings Services assigned its 'BB-' corporate credit rating to Las Vegas-based...

Companies mentioned in this report are: Tropicana Entertainment Inc.
Action: New Rating

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Tropicana Entertainment Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.